welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Lower Limb Flexibility in Duchenne Muscular Dystrophy: Effects on Functional Performance
study id #: NCT03534349
condition: Duchenne Muscular Dystrophy, Performance, Flexibility
The investigator investigated the effect of lower limb flexibility on functional performance of children with Duchenne Muscular Dystrophy.
mechanism of action: No pharmaceutical intervention
last updated: November 21, 2018
start date: January 2017
estimated completion: June 2017
size / enrollment: 30
Thirty children whose functional levels were in 1 or 2 according to the Brooke Lower Extremity Functional Classification Scale were included in the study. Flexibilities of hamstrings, hip flexors, tensor fascia latae, and gastrocnemius muscles were evaluated in dominant lower limb. Popliteal angle test, hip flexor flexibility test, tensor fascia latae flexibility test and gastrocnemius flexibility test were used for flexibility asssessments. Functional performance was assessed with 6 Minute Walk Test (6 MWT) and Timed Performance Tests. The correlation between the flexibility of lower limb muscles' and performance tests were examined.
- 6 Minute Walk Test [ Time Frame: 6 Minute ]
The 6 Minute Walk Test (6MWT) is a standard test recently used to evaluate functional capacity in neuromuscular diseases, and found to be a safe and valid test that can be performed in Duchenne Muscular Dystrophy
- Timed Performance Test [ Time Frame: 3 minute ]
Timed performance tests such as 10 m walk, Gower's (from supine position to stand up), ascending/descending 4 steps were also performed. During these tests, the child's performance was recorded in seconds.
• Having a Duchenne Muscular Dystrophy diagnosis,
• Being in the ambulatory period and climbing four steps independently,
• To be able to cooperate the physiotherapist's directions,
• Not having any severe contracture in the lower limbs which may prevent assessments,
• Not having any injury or surgery involving the lower limbs during the last 6 months.
Children who did not provide these criteria and did not will to participate the study were excluded.
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyThe main purpose of this study is to tes...
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dyst...Duchenne Muscular Dystrophy (DMD) is inh...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy ProgramSarepta Therapeutics, Inc., a commercial...
DMD clinical therapies II: P.133 The burden of participation in a clinical trial for boys with Duchenne muscular dys...Despite some medical breakthroughs in Du...